145 related articles for article (PubMed ID: 7736523)
1. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.
Haisma HJ; van Muijen M; Pinedo HM; Boven E
Cell Biophys; 1994; 24-25():185-92. PubMed ID: 7736523
[TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM
Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585
[TBL] [Abstract][Full Text] [Related]
3. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
4. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.
Houba PH; Leenders RG; Boven E; Scheeren JW; Pinedo HM; Haisma HJ
Biochem Pharmacol; 1996 Aug; 52(3):455-63. PubMed ID: 8687500
[TBL] [Abstract][Full Text] [Related]
5. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.
Vingerhoeds MH; Haisma HJ; Belliot SO; Smit RH; Crommelin DJ; Storm G
Pharm Res; 1996 Apr; 13(4):604-10. PubMed ID: 8710754
[TBL] [Abstract][Full Text] [Related]
6. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
7. Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy.
Houba PH; Boven E; Haisma HJ
Bioconjug Chem; 1996; 7(5):606-11. PubMed ID: 8889024
[TBL] [Abstract][Full Text] [Related]
8. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
9. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs.
Vingerhoeds MH; Haisma HJ; van Muijen M; van de Rijt RB; Crommelin DJ; Storm G
FEBS Lett; 1993 Dec; 336(3):485-90. PubMed ID: 8282116
[TBL] [Abstract][Full Text] [Related]
10. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.
Fonseca MJ; Jagtenberg JC; Haisma HJ; Storm G
Pharm Res; 2003 Mar; 20(3):423-8. PubMed ID: 12669963
[TBL] [Abstract][Full Text] [Related]
11. A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy.
Haisma HJ; Van Muijen M; Scheffer G; Scheper RJ; Pinedo HM; Boven E
Hybridoma; 1995 Aug; 14(4):377-82. PubMed ID: 8522350
[TBL] [Abstract][Full Text] [Related]
12. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives.
Roemhild K; Besse HC; Wang B; Peña Q; Sun Q; Omata D; Ozbakir B; Bos C; Scheeren HW; Storm G; Metselaar JM; Yu H; Knüchel-Clarke R; Kiessling F; Moonen CTW; Deckers R; Shi Y; Lammers T
Theranostics; 2022; 12(10):4791-4801. PubMed ID: 35832083
[No Abstract] [Full Text] [Related]
14. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
[TBL] [Abstract][Full Text] [Related]
15. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
[TBL] [Abstract][Full Text] [Related]
16. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
[TBL] [Abstract][Full Text] [Related]
17. Beta-glucuronidase-mediated drug release.
de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
[TBL] [Abstract][Full Text] [Related]
18. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
19. Glucuronides in anti-cancer therapy.
Chen X; Wu B; Wang PG
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):139-50. PubMed ID: 12678908
[TBL] [Abstract][Full Text] [Related]
20. Intensely cytotoxic anthracycline prodrugs: glucuronides.
Bakina E; Wu Z; Rosenblum M; Farquhar D
J Med Chem; 1997 Dec; 40(25):4013-8. PubMed ID: 9406592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
